A randomised crossover study comparing ramosetron plus dexamethasone with ramosetron alone in the prevention of cisplatin-induced emesis

Clinical Drug Investigation

Volumn 25, Issue 3, 2005, Pages 191-197

  Kim, Jeong Hye ^a   Kim, Tae Won ^b   Ryu, Min Hee ^b   Chang, Heung Moon ^b   Lee, Sang Hong ^b   Lee, Jung Shin ^b   Kang, Yoon Koo ^b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; IFOSFAMIDE; MESNA; RAMOSETRON;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG PREFERENCE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEAT SENSATION; HICCUP; HUMAN; INSOMNIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STOMACH CANCER;

EID: 16244396092     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525030-00005     Document Type: Article

References (24)

1. Kamato T, Miyata K, Ito H, et al. Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs. Jpn J Pharmacol 1991; 57 (3): 387-95
2. Kamato T, Ito H, Nagakura Y, et al. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Pharmacol 1993 Jul 20; 238 (2-3); 369-76
3. Kang YK, Park YH, Ryoo BY, et al. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res 2002; 30 (3): 220-9
4. Noda K, Ikeda M, Yoshida O, et al. Clinical evaluation of ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res 2002; 30 (3): 211-9
5. Cassileth PA, Lusk EJ, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 1983; 143 (7); 1347-9
6. D'Olimpio JT, Camacho F, Chandra P, et al. Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial. J Clin Oncol 1985; 3 (8): 1133-5
7. Aapro MS, Plezia PM, Alberts DS, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984: 2 (5): 466-71
8. Kirchner V, Aapro M, Terrey JP, et al. A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. Eur J Cancer 1997; 33 (10): 1605-10
9. Sorbe BG, Berglind AM, Andersson H, et al. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 1998; 83 (5): 1022-32
10. Sorbe BG, Hogberg T, Glimelius B, et al. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group. Anticancer Drugs 1995; 6 Suppl. 1: 31-6
11. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9 (4): 675-8
12. Garcia-del-Muro X, Vadell C, Perez Manga G, et al. Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer 1998; 34 (1): 193-5
13. Joss RA, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5 (3): 253-8
14. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12(3): 596-600
15. Liaw CC, Wang CH, Chang HK, et al. Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron. Am J Clin Oncol 2000; 23 (3): 253-7
16. Fauser AA, Pizzocaro G, Schueller J, et al. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 2000; 8 (1): 49-54
17. Taketani Y, Yoshikawa H, Kinoshita K, et al. Clinical evaluation of YM060 oral preparation in the treatment of nausea and vomiting induced by anticancer drugs: a phase-III repeated-dose study. World Obst Gyn 1996; 48 (8): 749-60
18. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. London: Chapman and Hall, 1989
19. Hills M, Armitage P. The two period cross-over clinical trial. Br J Clin Pharmacol 1979; 8 (1): 7-20
20. France LA, Lewis JA, Kay R. The analysis of failure time data in crossover studies. Stat Med 1991; 10 (10): 1099-113
21. Senn S. Cross-over trials in clinical research. Chichester: John Wiley & Sons Ltd. 1993
22. Noda K, Ikeda M, Taguchi T, et al. Clinical evaluation of YM060 oral preparation in the treatment of nausea and vomiting induced by the anticancer drug cisplatin: a phase 3 double-blind comparative study with ondansetron hydrochloride. J New Remedies Clinics 1996; 45: 1445-62
23. Villalon A, Chan V. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. The Phillippine Nausea Study Group. Support Care Cancer 2004; 12 (1): 58-63
24. Sekine I, Nishiwaki Y, Kakinuma R, et al. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol. 1996; 26 (3): 164-8